Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 33.2
(1.84%)
SEK 33.2
(1.84%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 170.44 Million SEK | 17.0% |
| 2022 | 145.67 Million SEK | 10.24% |
| 2021 | 132.14 Million SEK | -7.16% |
| 2020 | 142.33 Million SEK | 11.58% |
| 2019 | 127.56 Million SEK | 20.37% |
| 2018 | 105.97 Million SEK | -5.93% |
| 2017 | 112.66 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 45.97 Million SEK | 20.28% |
| 2024 Q3 | 64.61 Million SEK | 40.55% |
| 2024 Q1 | 38.22 Million SEK | -33.38% |
| 2023 FY | 170.44 Million SEK | 17.0% |
| 2023 Q3 | 40.3 Million SEK | -2.55% |
| 2023 Q2 | 41.35 Million SEK | 0.35% |
| 2023 Q1 | 41.2 Million SEK | 0.49% |
| 2023 Q4 | 57.37 Million SEK | 42.37% |
| 2022 Q2 | 38.41 Million SEK | 18.07% |
| 2022 Q1 | 32.54 Million SEK | 20.06% |
| 2022 Q3 | 33.7 Million SEK | -12.26% |
| 2022 FY | 145.67 Million SEK | 10.24% |
| 2022 Q4 | 41 Million SEK | 21.66% |
| 2021 Q4 | 27.1 Million SEK | -27.09% |
| 2021 Q3 | 37.17 Million SEK | 1.91% |
| 2021 Q2 | 36.47 Million SEK | 19.87% |
| 2021 Q1 | 30.42 Million SEK | -6.35% |
| 2021 FY | 132.14 Million SEK | -7.16% |
| 2020 Q4 | 32.49 Million SEK | 2.89% |
| 2020 Q2 | 36.9 Million SEK | -4.87% |
| 2020 FY | 142.33 Million SEK | 11.58% |
| 2020 Q1 | 38.79 Million SEK | -19.31% |
| 2020 Q3 | 31.57 Million SEK | -14.43% |
| 2019 Q3 | 16.39 Million SEK | -45.48% |
| 2019 Q4 | 48.07 Million SEK | 193.23% |
| 2019 FY | 127.56 Million SEK | 20.37% |
| 2019 Q2 | 30.07 Million SEK | -3.81% |
| 2019 Q1 | 31.26 Million SEK | 0.0% |
| 2018 FY | 105.97 Million SEK | -5.93% |
| 2017 FY | 112.66 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -193.321% |
| Ziccum AB (publ) | 3.74 Million SEK | -4448.706% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 72.331% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -237.605% |
| Mendus AB (publ) | 28.48 Million SEK | -498.308% |
| Genovis AB (publ.) | 158.23 Million SEK | -7.715% |
| Intervacc AB (publ) | 8.01 Million SEK | -2026.513% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -3796.662% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -288.281% |
| Aptahem AB (publ) | 2.63 Million SEK | -6379.012% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -16367.633% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -221250.649% |
| Fluicell AB (publ) | 3.33 Million SEK | -5006.052% |
| Saniona AB (publ) | 16.84 Million SEK | -912.114% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -938.825% |
| Biovica International AB (publ) | 7.29 Million SEK | -2237.997% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -14067.914% |
| AcouSort AB (publ) | 10.55 Million SEK | -1515.392% |
| Xintela AB (publ) | 78 Thousand SEK | -218412.821% |
| Abliva AB (publ) | 137 Thousand SEK | -124308.759% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -195.903% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -8362.761% |
| OncoZenge AB (publ) | 3000.00 SEK | -5681233.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -109861.29% |
| CombiGene AB (publ) | 5.54 Million SEK | -2974.25% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 85.878% |
| Camurus AB (publ) | 1.71 Billion SEK | 90.073% |
| Corline Biomedical AB | 25.03 Million SEK | -580.943% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -2901.761% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -23539.39% |
| I-Tech AB | 120.86 Million SEK | -41.022% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | -27.105% |
| Cyxone AB (publ) | 5.14 Million SEK | -3210.8% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -2317.589% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -1498.17% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -1417.712% |
| Nanologica AB (publ) | 1.44 Million SEK | -11711.504% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -321484.906% |
| BioInvent International AB (publ) | 71.46 Million SEK | -138.508% |
| Alzinova AB (publ) | 270 Thousand SEK | -63025.926% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -383.93% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -11549.875% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -5939.688% |
| Simris Alg AB (publ) | 4.35 Million SEK | -3814.561% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -131007.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 28.605% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -740943.478% |